SpringWorks Therapeutics Q3 2021 Earnings Report
Key Takeaways
SpringWorks Therapeutics reported a net loss of $41.0 million, or $0.84 per share, for the third quarter of 2021. As of September 30, 2021, cash, cash equivalents and marketable securities were $480.6 million.
Advanced into Randomized Phase 2 Expansion and Addition of New Sub-studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma.
Expanded Targeted Oncology Pipeline with In-License of Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors.
Initiated Mirdametinib Phase 1/2 Basket Study in ER+ Metastatic Breast Cancer and MEK 1/2 Mutant Solid Tumors.
Announced Issuance of New U.S. Composition of Matter Patents to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041.